BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB: IXSBF) (TSX VENTURE: IXS) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™)technology, will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference in Monaco, May 20th, and the Henry Kunkel Society Annual Meeting in Italy, May 21st-May 24th.
